The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Outlook Therapeutics Inc shares valued at $28,446 were purchased by KENYON LAWRENCE A on Sep 26 ’24. At $5.69 per share, KENYON LAWRENCE A acquired 5,000 shares. The insider’s holdings grew to 5,946 shares worth approximately $31335.42 following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Haddadin Yezan Munther purchased 1,882 shares, netting a total of over 22,242 in proceeds. Following the buying of shares at $11.82 each, the insider now holds 5,049 shares.
Before that, Evanson Jeff had added 62,484 shares to its account. In a trade valued at $26,243, the CHIEF COMMERCIAL OFFICER bought Outlook Therapeutics Inc shares for $0.42 each. Upon closing the transaction, the insider’s holdings increased to 62,484 shares, worth approximately $4.26 million.
As published in a research note from BTIG Research on March 27, 2024, Outlook Therapeutics Inc [OTLK] has been rated up from a Neutral to a Buy and the price target has been revised to $50. Analysts at Chardan Capital Markets upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in mid February. As of January 25, 2024, Guggenheim has increased its “Neutral” rating to a “Buy” for OTLK. Earlier on December 27, 2023, CapitalOne upgraded its rating. Their new recommendation was “an Overweight” for OTLK stock which previously was a “an Equal weight”.
Analyzing OTLK Stock Performance
During the last five days, there has been a surge of approximately 1.54%. Over the course of the year, Outlook Therapeutics Inc shares have dropped approximately -33.12%. Nevertheless, trading volume fell to 0.54 million shares from 0.51 million shares the previous day.
Support And Resistance Levels for Outlook Therapeutics Inc (OTLK)
RSI (Relative Strength Index) is 42.53 on the 14-day chart, showing neutral technical sentiment.
Which companies own the most shares of Outlook Therapeutics Inc (OTLK)?
On August 31, 2023, H.C. Wainwright assigned a price target of “a Neutral” to the stock and downgraded coverage with a $1.
